Literature DB >> 22352278

[Six-month follow-up study of drug treatment for cannabis addiction: comparison study of four drugs].

Netta Shoenfeld1, Dana Bodnik, Oded Rosenberg, Moshe Kotler, Pinhas Dannon.   

Abstract

OBJECTIVES: Marijuana addiction is one of the most common forms of addiction worldwide. A variety of reasons for use exist, however, there are only a few tested treatments with frequent relapses. In this study, we examined the efficacy of four pharmacotherapy agents for the treatment of marijuana addiction: naltrexone, bupropion, escitalopram and bromazepam.
MATERIALS AND METHODS: A total of 59 patients were randomly assigned into four groups. Each group received one of the pharmacological agents for 120 days. Four types of questionnaires were employed: The Hamilton Rating Scale for Depression--21 items, the Hamilton Rating Scale for Anxiety, the Global Assessment of Functioning and a Visual Analogue Scale for perceived need of the drug. In addition, random urine tests were performed to detect tetrahydrocannabinol [THC).
RESULTS: Naltrexone proved to be the most efficacious of the four agents, with only four dropouts. Other agents proved less efficacious with six, seven and eights dropouts for bupropion, bromazepam and escitalopram, respectively. In addition, naltrexone was most efficacious in reducing anxiety and depression rates, and increasing functioning and perceived need for drug use.
CONCLUSION: Out of four pharmacological agents, naltrexone proved to be most efficacious in treating marijuana addiction and related disorders. Further studies are needed to confirm our results.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22352278

Source DB:  PubMed          Journal:  Harefuah        ISSN: 0017-7768


  1 in total

1.  Inpatient detoxification from a synthetic cannabinoid and control of postdetoxification cravings with naltrexone.

Authors:  Christopher J C Rodgman; Christopher D Verrico; Ray B Worthy; Erica E Lewis
Journal:  Prim Care Companion CNS Disord       Date:  2014-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.